Abstract:Bleeding and thrombosis represent common complications in myeloproliferative neoplasms (MPN) and significantly contribute to morbidity and mortality. Molecular markers, including CALR mutations, were considered not only as diagnostic markers, but also as risk factors for bleeding and thrombosis associated with MPN, especially for patients in remote primary hospitals. We sought to develop an easy-to-use assay for the rapid detection of CALR type 1 (CALR-1) and type 2 (CALR-2) mutations in Philadelphia chromosome-negative MPN patients. Peptide nucleic acid-locked nucleic acid (PNA-LNA) clamping loop-mediated isothermal amplification (LAMP) assays were established, which were integrated into a centrifugal compact disc (CD) microfluidic platform. A total of 158 clinical blood samples were tested simultaneously by this microfluidic platform and an in-house real time PCR assay. The detection performance of the LAMP arrays was validated and conflicting results were identified by Sanger sequencing. The results suggested that the LAMP methods we developed exhibited good sensitivity, specificity, and precision. By real time fluorescence assay the detection limit for CALR-1 and CALR-2 mutations could reach as low as 1% and 0.5% respectively, and 10% and 5% respectively by visual method. There were no nonspecific background amplifications among different detection systems. For the CALR-1 and CALR-2 LAMP detection systems, intra-batch CV values of 1% mutated plasmid were 10.56% and 10.51% respectively, and the inter-batch CV values were 19.55% and 18.39%, respectively. The products were all analyzed by melting curve analysis and electrophoresis followed by Sanger sequencing analysis, which were consistent with the database sequences. The microfluidic platform could complete rapid detection of CALR-1/2 mutations within 60 min. The results of clinical samples detected by our CD-like microfluidic chipLAMP assay and rtPCR assay suggested that 133 samples were CALR wild type, 15 were CALR-1 mutation type, and 9 were CALR-2 mutation type. The correlation coefficient value (Kendall's tau_b) of the two assays was 0.99. Interestingly, by the newly established detection platform, we were surprised to find that one patient of Chinese origin harbored both CALR-1 and CALR-2 mutations. This result was verified by Sanger sequencing analysis. The LAMP detection systems developed herein displayed good sensitivity, specificity, and stability. Additionally, the detection results could be directly judged by color changes of the reaction systems without any auxiliary equipment. Thus, the platform we developed has the potential of being widely used in remote and economically undeveloped areas in the future.

A multiplex snapback primer system for the enrichment and detection of JAK2 V617F and MPL W515L/K mutations in Philadelphia-negative myeloproliferative neoplasms.

A Multiplex Snapback Primer System for the Enrichment and Detection Ofjak2v617f Andmplw515l/k Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Establishment of a Rapid and Easy Method for Simultaneous Detection of FLT3-ITD and NPM1 Gene Mutations in Acute Myeloid Leukemia

A portable microfluidic platform for rapid molecular diagnostic testing of patients with myeloproliferative neoplasms

Multiplex sequence-specific PCR detection for simultaneous screening of 5 types of JAK2 mutations in myeloproliferative diseases

Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR

Establishment of Scalable Nanoliter Digital LAMP Technology for the Quantitative Detection of Multiple Myeloproliferative Neoplasm Molecular Markers

MPL W515L/K mutations in 343 Chinese adults with JAK2V617F mutation-negative chronic myeloproliferative disorders detected by a newly developed RQ-PCR based on TaqMan MGB probes.

Toward point-of-care testing for JAK2 V617F mutation on a microchip

Detection of the Jak2 Mutation in Myeloproliferative Neoplasms by Asymmetric Pcr with Unlabeled Probe and High-Resolution Melt Analysis

The Overall Analysis of JAK2 and MPL Mutation Status in Chinese MPD Patients by MassARRAY Assay

Development and Validation of a Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-Assay for Clinical JAK2 V617F Mutation Detection

Development And Inter-Laboratory Validation Of Unlabeled Probe Melting Curve Analysis For Detection Of Jak2 V617f Mutation In Polycythemia Vera

Crispr/Cas12a-Based Ultrasensitive And Rapid Detection Of Jak2 V617f Somatic Mutation In Myeloproliferative Neoplasms

The Mutation Profile of JAK2 and CALR in Chinese Han Patients with Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Simultaneous Detection of JAK2 V617F Mutation and JAK2 Exon12 Mutations by Multiplex PCR and High-Resolution Melting Curve Analysis

[Detection of JAK2V617F Mutation in Patients with Myeloproliferative Disorders with TaqMan-MGB Probe].

Rapid detection of CALR type 1 and type 2 mutations using PNA-LNA clamping loop-mediated isothermal amplification on a CD-like microfluidic chip

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Clinical validation of long-range PCR assay for MLL partial tandem duplications for acute myeloid leukemia.